Subclassification of epithelioid sarcoma with potential therapeutic impact

Simon Haefliger, Olga Chervova, Christopher Davies, Steven Nottley, Steven Hargreaves, Vaiyapuri P. Sumathi, Fernanda Amary, Roberto Tirabosco, Nischalan Pillay, Stephan Beck, Adrienne M. Flanagan*, Iben Lyskjær

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Abstract

Epithelioid sarcoma is a rare and aggressive mesenchymal tumour, the genetic hallmark of which is the loss of expression of SMARCB1, a key member of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodelling complex. Hampered by its rarity, epithelioid sarcoma has received little research attention and therapeutic options for this disease remain limited. SMARCB1-deficient tumours also include malignant rhabdoid tumour, atypical teratoid and rhabdoid tumour, epithelioid malignant peripheral nerve sheath tumour, and poorly differentiated chordoma. Histologically, it can be challenging to distinguish epithelioid sarcoma from malignant rhabdoid tumour and other SMARCB1-deficient tumours, whereas methylation profiling shows that they represent distinct entities and facilitates their classification. Methylation studies on SMARCB1-deficient tumours, although not including epithelioid sarcomas, reported methylation subgroups which resulted in new clinical stratification and therapeutic approaches. In addition, emerging evidence indicates that immunotherapy, including immune checkpoint inhibitors, represents a promising therapeutic strategy for SMARCB1-deficient tumours. Here, we show that some epithelioid sarcomas share methylation patterns of malignant rhabdoid tumours indicating that this could help to distinguish these entities and guide treatment. Using gene expression data, we also showed that the immune environment of epithelioid sarcoma is characterised by a predominance of CD8+ lymphocytes and M2 macrophages. These findings have potential implications for the management of patients with epithelioid sarcoma.

OriginalsprogEngelsk
TidsskriftJournal of Pathology
Vol/bind260
Nummer4
Sider (fra-til)368-375
Antal sider8
ISSN0022-3417
DOI
StatusUdgivet - aug. 2023

Fingeraftryk

Dyk ned i forskningsemnerne om 'Subclassification of epithelioid sarcoma with potential therapeutic impact'. Sammen danner de et unikt fingeraftryk.

Citationsformater